A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer

NCT ID: NCT01746771

Last Updated: 2016-03-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 44 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-11-30
• Study Completion Date: 2015-08-31

Brief Summary

[Phase I] The main objective of this study is to evaluate the safety, tolerability and determine the Recommended Dose (RD) of HM781-36B(Poziotinib)combined with Paclitaxel and Trastuzumab

[Phase II] The main objective of this study is to evaluate anticancer activity through determination of response rate of HM781-36B(Poziotinib)combined with Paclitaxel and Trastuzumab in patients with HER-2 positive advanced gastric cancer

Detailed Description

Besides the main objectives, there are other objectives as follows:

[Phase I]

1. To assess the pharmacokinetic profile of HM781-36B(Poziotinib) combined with Paclitaxel and Trastuzumab

2. To evaluate anticancer activity of HM781-36B(Poziotinib) combined with Paclitaxel and Trastuzumab in patients with HER-2 positive advanced gastric cancer

3. To evaluate PFS(Progression-Free Survival), TTP (Time To Tumor Progression), and DOR (Duration of Overall Response)

[Phase II]

1. To assess the safety, tolerability of HM781-36B(Poziotinib) combined with Paclitaxel and Trastuzumab

2. To evaluate tumor response through determination of disease control rate , PFS(Progression-Free Survival), TTP (Time To Tumor Progression), and DOR (Duration of Overall Response)

Conditions

HER-2 Positive Advanced Gastric Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HM781-36B, Paclitaxel, Trastuzumab

HM781-36B(Poziotinib): QD\*2weeks/3weeks Paclitaxel: 175mg/m2 Trastuzumab(Herceptin): 8mg/kg

Group Type: EXPERIMENTAL

HM781-36B(Poziotinib)

Intervention Type: DRUG

QD\*2weeks/3weeks

Paclitaxel

Intervention Type: DRUG

175mg/m2

Trastuzumab

Intervention Type: DRUG

8mg/kg

Interventions

HM781-36B(Poziotinib)

QD\*2weeks/3weeks

Intervention Type: DRUG

Paclitaxel

175mg/m2

Intervention Type: DRUG

Trastuzumab

8mg/kg

Intervention Type: DRUG

Other Intervention Names

NOV120101; Poziotinib; Herceptin

Eligibility Criteria

Inclusion Criteria

1. Histologically or cytologically confirmed advanced gastric cancer including gastroesophageal junction adenocarcinoma

2. At least one measurable lesion defined by RECIST(v1.1)

3. FISH+ or IHC3+ (regardless of FISH results)

4. Age≥19

5. ECOG ≤ 2

6. Life expectancy ≥ 12 weeks

7. Adequate bone marrow and no abnormal heart and lung function

8. No radiotherapy, other anticancer drugs or immunotherapy is allowed during this study

9. Subjects must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow up assessments and procedures

Exclusion Criteria

1. Patients with a history of hypersensitivity to Trastuzumab and who have been treated with medicine including Cremophor EL

2. Patients who have a current active malignancy other than gastric adenocarcinoma (with exception of non-melanoma skin cancer or cervical cancer in situ)

3. Patients who have previously received taxane-based chemotherapy

4. The presence of central nervous system metastases

5. Patients who have a blood tumor such as leukemia, or who had previously received, or are planning to receive, the bone marrow transplant

6. Patients with uncontrolled infection

7. Patients who have GI malabsorption or difficulty taking oral medication

8. Patients with following diseases are excluded:

9. Patients with psychiatric or congenital disorder which can affect adherence or make hard to follow the requirements of the protocol

10. Pregnant or breastfeeding women or women of childbearing who do not use an appropriate method of contraception (male patient should also use an appropriate method of contraception)

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National OncoVenture

OTHER

Sponsor Role: collaborator

Hanmi Pharmaceutical Company Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

YoHan Kim, M.D.

Role: STUDY_DIRECTOR

Hanmi Pharmaceutical Company Limited

Locations

Seoul National University Hospital

Seoul, , South Korea

Countries

South Korea

Other Identifiers

HM-PHI-A201

Identifier Type: -

Identifier Source: org_study_id